OM1 (Major Depression Outcomes) 聯繫信件

目標：探討精神科用藥合作 優先級：中（Phase 3） 聯繫方式：

一般諮詢: info@om1.com
行銷副總裁: Renee Hurley (rhurley@om1.com, 617-620-9571)
電話: +1 (888) 324 3899
地址: 31 St. James Ave Suite #1010, Boston MA 02116

信件內容

Subject: Collaboration Inquiry: AI Drug Repurposing for Treatment-Resistant Depression

Dear OM1 Team,

I am writing regarding a potential collaboration between TwTxGNN and your Major Depression Outcomes application, which tracks PHQ-9 scores and treatment responses.

About TwTxGNN

TwTxGNN is an open-source drug repurposing platform that uses Harvard's TxGNN knowledge graph model to predict new therapeutic uses for existing medications.

Psychiatric Coverage:

14 drugs with psychiatric disease predictions
8 predicted indications
Includes depression, anxiety, and related conditions
Evidence levels from L1 (RCTs) to L5 (AI prediction)

Platform Stats:

189 total drugs analyzed
1,268 predicted new indications
222,391 DDI records for safety checking

Website: https://twtxgnn.yao.care/ GitHub: https://github.com/yao-care/TwTxGNN

Integration Opportunity

The Major Depression Outcomes app's longitudinal tracking of PHQ-9 scores creates a unique opportunity:

Treatment Response Monitoring
- When PHQ-9 scores indicate inadequate treatment response
- TwTxGNN can suggest drug repurposing candidates
- Support shared decision-making with evidence-based alternatives
Personalized Suggestions
- Based on patient's medication history
- Avoiding drugs with known interactions
- Prioritizing candidates with clinical trial support
Outcome Validation
- Track PHQ-9 changes in patients receiving repurposed drugs
- Generate real-world evidence for AI predictions
- Contribute to research on treatment-resistant depression

Proposed Integration Flow

PHQ-9 Assessment
       ↓
Score Indicates Poor Response
       ↓
Query TwTxGNN for Alternatives
       ↓
Display Candidates with Evidence
       ↓
Shared Decision-Making
       ↓
Track Outcomes (PHQ-9 Changes)

Safety Considerations

We understand the sensitivity of psychiatric medications. TwTxGNN includes:

Safety Feature	Implementation
DDI Checking	222,391 drug pairs from DDInter
Evidence Levels	L1-L5 classification
Disclaimers	Clear research-only labeling
References	ClinicalTrials.gov + PubMed links

All predictions are clearly labeled as research findings requiring clinical validation.

Technical Compatibility

Item	TwTxGNN	OM1 Major Depression
FHIR Version	R4	R4 (also DSTU2, STU3)
Integration	REST API	SMART on FHIR
Data Format	FHIR JSON	Standard FHIR

Next Steps

Would you be interested in:

A technical discussion on integration options?
Reviewing our psychiatric drug predictions?
Exploring a pilot study for treatment-resistant depression?

We believe this collaboration could provide valuable additional options for patients who have not responded to first-line treatments.

Best regards,

TwTxGNN Team https://twtxgnn.yao.care/

附件清單

英文版專案簡介：project-intro-en.md
FHIR API 規格：api-spec.md
精神疾病藥物預測清單
免責聲明文件

背景資料

OM1

健康科技公司，專注於真實世界資料分析
Major Depression Outcomes 應用追蹤 PHQ-9 評分
支援多種 FHIR 版本

PHQ-9 評分

Patient Health Questionnaire-9
抑鬱症嚴重程度評估
0-4: 無或極輕
5-9: 輕度
10-14: 中度
15-19: 中重度
20-27: 重度

安全考量

精神科用藥需特別注意：

藥物交互作用（特別是 MAOI、SSRI、抗精神病藥）
自殺風險（特別是青少年）
戒斷症狀
QT 延長風險

必須包含免責聲明：所有預測僅供研究參考，不構成醫療建議。

待辦事項

建立日期：2026-03-01